Researchers have demonstrated that a modified form of vitamin B12, called nitrosylcobalamin (NO-Cbl), can cross the blood-brain barrier in experimental models. The analogue was engineered to carry nitric oxide, a molecule known to kill tumour cells selectively. In laboratory tests, the compound successfully penetrated the barrier that typically blocks many therapeutic agents from reaching brain tissue.
The blood-brain barrier protects the central nervous system but also limits treatment options for brain cancers. NO-Cbl's ability to traverse this barrier while delivering a cytotoxic payload represents a mechanistic advance in drug delivery design. The study showed the analogue retained its tumour-targeting properties after crossing into brain tissue.
The research remains at the preclinical stage. Investigators emphasize that significant further work, including toxicity profiling and efficacy testing in more complex models, is required before any clinical application can be considered. No human trials have been initiated.
The findings were reported in a peer-reviewed publication, though the source material does not specify the journal or institutional affiliations. The work contributes to ongoing efforts to develop targeted therapies for central nervous system malignancies.
Scientists caution that blood-brain barrier penetration alone does not guarantee therapeutic success. Factors such as distribution within the tumour microenvironment, clearance rates, and potential off-target effects remain to be characterized in subsequent studies.
What does the new research on Vitamin B12-based therapy for brain cancer reveal?
This is an independent summary. The complete reporting, supporting context and any primary documents remain with The Hindu.